




RealRate

PHARMACEUTICAL 2022

PLx Pharma Inc.
Rank 341 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

PLx Pharma Inc.
Rank 341 of 475



The relative strengths and weaknesses of PLx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLx Pharma Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 134% points. The greatest weakness of PLx Pharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 196% points.

The company's Economic Capital Ratio, given in the ranking table, is -257%, being 20% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	73,476
Cost of Goods Sold	4,805
Intangible Assets	2,061
Liabilities, Current	11,879
Liabilities, Non-Current	136
Other Assets	247
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12,947
Other Net Income	-5,335
Property and Equipment	858
Research and Development	4,182
Revenues	8,208
Selling, General and Administrative Expense	40,011

Output Variable	Value in 1000 USD
Assets	76,642
Liabilities	24,962
Expenses	48,998
Stockholders Equity	51,680
Net Income	-46,125
Comprehensive Net Income	-46,125
Economic Capital Ratio	-257%

